SmithKline prepared to defend Tagamet HB packaging from private-label imitators.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE WARNS OF LEGAL CAMPAIGN TO PROTECT TAGAMET HB PACKAGING in communications to private-label OTC drug manufacturers. Speaking at a Healthcare Businesswomen's Association seminar on Rx-to-OTC switch strategies March 5 in Philadelphia, SmithKline Beecham Director-Marketing Managed Care Bruce Taylor said the company has "communicated" to private-label manufacturers that it will "be aggressive legally" in protecting Tagamet HB packaging from imitators.